-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LTI-01 in Empyema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LTI-01 in Empyema report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LTI-01 in Empyema Drug Details: LTI-01 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LTI-03 in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LTI-03 in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LTI-03 in Idiopathic Pulmonary Fibrosis Drug Details: LTI-03 is under development...
-
Product Insights
Zelzate – LTi REEnergy Solar PV Park
Zelzate - LTi REEnergy Solar PV Park is a solar PV project located in East Flanders, Belgium. The project came online in 2013. Empower your strategies with our Zelzate - LTi REEnergy Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LTI-01 in Empyema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LTI-01 in Empyema report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.LTI-01 in EmpyemaDrug Details:LTI-01 is under development for the treatment of loculated pleural effusions...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LTI-01 in Pleural Effusion
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LTI-01 in Pleural Effusion report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.LTI-01 in Pleural Effusion Drug Details:LTI-01 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LTI-03 in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LTI-03 in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.LTI-03 in Idiopathic Pulmonary Fibrosis Drug Details:LTI-03 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cobimetinib Fumarate in Craniopharyngioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cobimetinib Fumarate in Craniopharyngioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cobimetinib Fumarate in Craniopharyngioma Drug Details: Cobimetinib (GDC-0973 / RG7421 /...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NUV-655 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NUV-655 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NUV-655 in Solid Tumor Drug Details:NUV-655 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NAS-150 in Pulmonary Radiation Toxicity
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.NAS-150 in Pulmonary Radiation ToxicityDrug Details:NAS-150 (AEOL-10150) is under development for the treatment of idiopathic pulmonary...
-
Thematic Analysis
IT Services Sector Scorecard, Q3 2023 Update – Thematic Intelligence
Companies scoring strongly in the cloud, data analytics, and future of work themes lead the thematic screen of GlobalData’s IT services sector scorecard. Global IT services giants Accenture, IBM, and Infosys top the thematic rankings, closely followed by Capgemini and Tata Consultancy Services. The Indian heritage vendors make up half of the top 10 vendor positions, suggesting they have successfully adapted their strategies to the long-term concern of a declining cost advantage versus their US and European peers.